- Home
- YDKG vs OVID Comparison
YDKG vs OVID Comparison
Compare YDKG & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YDKG
- OVID
- Stock Information
- Founded
- YDKG 2005
- OVID 2014
- Country
- YDKG China
- OVID United States
- Employees
- YDKG N/A
- OVID N/A
- Industry
- YDKG Advertising
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- YDKG Consumer Discretionary
- OVID Health Care
- Exchange
- YDKG Nasdaq
- OVID Nasdaq
- Market Cap
- YDKG 99.8M
- OVID 117.3M
- IPO Year
- YDKG N/A
- OVID 2017
- Fundamental
- Price
- YDKG $0.07
- OVID $1.72
- Analyst Decision
- YDKG
- OVID Strong Buy
- Analyst Count
- YDKG 0
- OVID 4
- Target Price
- YDKG N/A
- OVID $3.13
- AVG Volume (30 Days)
- YDKG 156.4M
- OVID 5.3M
- Earning Date
- YDKG 11-17-2025
- OVID 11-11-2025
- Dividend Yield
- YDKG N/A
- OVID N/A
- EPS Growth
- YDKG N/A
- OVID N/A
- EPS
- YDKG N/A
- OVID N/A
- Revenue
- YDKG $13,107,000.00
- OVID $6,651,000.00
- Revenue This Year
- YDKG N/A
- OVID $1,086.57
- Revenue Next Year
- YDKG N/A
- OVID N/A
- P/E Ratio
- YDKG N/A
- OVID N/A
- Revenue Growth
- YDKG 2175.52
- OVID 1070.95
- 52 Week Low
- YDKG $0.04
- OVID $0.24
- 52 Week High
- YDKG $4.72
- OVID $2.01
- Technical
- Relative Strength Index (RSI)
- YDKG N/A
- OVID 57.35
- Support Level
- YDKG N/A
- OVID $1.50
- Resistance Level
- YDKG N/A
- OVID $1.68
- Average True Range (ATR)
- YDKG 0.00
- OVID 0.14
- MACD
- YDKG 0.00
- OVID -0.02
- Stochastic Oscillator
- YDKG 0.00
- OVID 61.37
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.